KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
发明人:
KIM, Seyun,김세윤,KIM, Eunha,김은하,BEON, Jiyoon,변지윤
申请号：
KRKR2018/000203
公开号：
WO2018/128429A1
申请日:
2018.01.04
申请国别(地区):
WO
年份:
2018
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, containing an inositol polyphosphate multikinase inhibitor as an active ingredient. Specifically, IPMK-depleted mice have a higher survival rate for sepsis than wild-type mice, and an increase in mRNA and protein expression of inflammatory cytokines such as IL-1β, IL-6 and TNF-α within tissue is inhibited when endotoxemia is induced, and thus the composition containing an IPMK inhibitor can be useful for treating inflammatory diseases.La présente invention concerne une composition pharmaceutique permettant de prévenir ou de traiter des maladies inflammatoires, contenant un inhibiteur dinositol polyphosphate multikinase (IPMK) utilisé comme principe actif. Plus particulièrement, les souris dépourvues dIPMK présentent un taux de survie à une septicémie plus élevé que celui de souris de type sauvage, et une augmentation de lexpression de lARNm et de protéines de cytokines inflammatoires telles que lIL-1β, lIL-6 et le TNF-α dans les tissus est inhibée lorsquune endotoxémie est induite, et ainsi la composition contenant un inhibiteur de lIPMK peut être utile pour le traitement de maladies inflammatoires.본 발명은 이노시톨 다인산 멀티키나아제 억제제를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 구체적으로, IPMK가 제거된 생쥐는 야생형 생쥐에 비해 패혈증에 대한 생존율이 높고, 내독소혈증 유도시 조직 내 IL-1β, IL-6 및 TNF-α와 같은 염증성 사이토카인의 mRNA 및 단백질 발현량의 증가가 억제되므로, IPMK 억제제를 함유하는 조성물은 염증성 질환의 치료에 유용하게 사용될 수 있다.
